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The dopamine-D2-receptor agonist ropinirole exerts neuroprotective
activity. Assuming that this neuroprotection might be associated with
inhibition of the apoptotic cascade underlying cell death, we examined a
possible effect ropinirole on the permeability transitionpore (mtPTP) in the
mitochondrial inner membrane. Using isolated rat liver mitochondria, the
effect of ropinirolewas studied onCa2+-triggered large-amplitude swelling,
membrane depolarization and cytochrome c release. In addition, the effect
of ropinirole on oxidation of added, membrane-impermeable NADH was
investigated. The results revealed doubtlessly, that ropinirole can inhibit
permeability transition. In patch-clamp experiments on mitoplasts, we
show directly that ropinirole interacts with the mtPTP. Thus, ropinirole
reversibly inhibits the opening of mtPTP with an IC50 of 3.4 µM and a Hill
coefficient of 1.3. In both systems (i.e. energized mitochondria and
mitoplasts) the inhibitory effect on permeability transition was attenuated
by increasing concentrations of inorganic phosphate. In addition, we
showed with antimycin A-treated mitochondria that ropinirole failed to
suppress respiratory chain-linked ROS release. In conclusion, our data
suggest that theneuroprotectiveactivityof ropinirole is due to the inhibition
of the release of apoptogenic factors frommitochondria.
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Amyotrophic lateral sclerosis (ALS) has been commonly
regarded as a neurodegenerative disorder primarily involving the
pyramidal motor system. There is however some evidence that
disease-related degenerative changes also occur in extraneural
tissues. Therefore, primary skin fibroblast cultures from ALS
patients were analysed for mitochondrial anomalies. To verify the
putative impairment of mitochondrial function in fibroblasts of
patients with ALS, the oxygen consumption (respiration rate) of
fibroblasts was measured using a high resolution oxygraph. To
check possible metabolic consequences of altered mitochondrial
function enzyme activity of aconitase (which harbors a highly
ROS-sensitive iron–sulfur-cluster) was determined. Furthermore,
mitochondrial DNA copy number analysis and deletion screening
were performed. Age matched healthy subjects served as controls.
We observed slightly lower maximal rates with NAD-dependent
substrates glutamate+malate in the fibroblasts of ALS patients
compared to controls. The succinate supported maximal respiration
rates in the fibroblasts from these patients were also lower.
Statistically significant deficiencies of respiratory chain complexes I
(NADH:CoQ1 oxidoreductase) and IV (cytochrome c oxidase, COX)
were identified by determination of elevated flux control coeffi-
cients of respiration in titrations with specific inhibitors (amytal
for complex I and azide for complex IV). Furthermore, the
aconitase activity levels were altered and diminished levels of
mitochondrial DNA copies were also observed in ALS fibroblasts.
Our results clearly show mitochondrial impairment in extracerebral
tissue (fibroblasts) of patients with ALS. We propose that the
mitochondrial changes described might potentially serve as
biomarkers that allow objective ALS patient diagnosis and
therapeutic monitoring in an accessible, peripheral tissue.
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